OBJECTIVE： To discuss the clinical distribution， enzyme production and drug resistance of Elizabethkingia meningospetica in our hospital， and to provide evidence for clinical treatment and infection prevention. METHODS： Clinical information of the patients with hospital infection caused by E. meningospetica were analyzed retrospectively during 2011-2015. Automatic bacterial identification apparatus and K-B assay were used for bacterial identification and drug sensitivity test. Phenotype of ESBLs， AmpC and MBL were determined by K-B assay， double-disc synergy method and modified three-dimensional test. RESULTS： 76 strains of E. meningospetica were isolated， mainly from sputum sample （75.0％）； the patients mainly came from the intensive care unit （57.9％）. 76 strains of E. meningospetica were completely resistant to 7 antibiotics as imipenem， meropenem PMB to bramycin， gentamicin， amikacin and cefepime； resistant rate to rifampin， SMZ and 3 kinds of enzyme inhibitors were all lower than 30％； resistant rate to vancomycin and minocycline were equal to 0.58 strain of ESBLs-producing bacterial （76.3％） and 47 strains of MBL-producing bacterial （61.8％） were detected， and no AmpC-producing bacterial was found. CONCLUSIONS： E. meningospetica will cause hospital infection in low immunity patients； the bacterial is highly resistant to antibiotics， which is correlated to high detection rate of ESBLs and MBL. Vancomycin and minocycline are first choice for E. meningospetica therapy.